| Overview |
| bs-11539R |
| CHN 1/Alpha-chimerin Polyclonal Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
| Human, Mouse, Rat, Dog, Cow, Sheep, Horse |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Alpha-chimerin |
| 151-250/459 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| Cytoplasm |
| A-chimaerin; Alpha-chimerin; ARHGAP2; CHIN_HUMAN; CHN; Chn1; N chimaerin; N chimerin; N-chimaerin; N-chimerin; NC; Rho GTPase-activating protein 2; RHOGAP2. |
| The Rac-GAP chimaerin family member Alpha-chimaerin (also known as N-chimaerin or rho GTPase-activating protein 2) has two splice variants: Alpha1 and Alpha2. The ?-chimaerin variant is a neuron-specific, diacylglycerol-binding and GTPase-activating protein for ras-related protein Rac 1. This variant lacks the N-terminal SH2 domain that is present in the Alpha2 variant. By inactivating Rac 1, Alpha1-chimaerin plays a significant role in the regulation of dendritic growth during neuronal development. It is recruited to the plasma membrane by phospholipase C Beta-coupled cell surface receptors activating the downstream generation of DAG (diacylglycerol). Overexpression of Alpha1-chimaerin results in dendritic spine retraction and the loss of dendritic branches. In the presence of reduced neuronal activity, Alpha1-chimaerin expression is down-regulated resulting in an increase in spine growth and dendritic branching. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| ICC |
1:100-500 |
Powered by Bioz